Approfondimenti generali
American Society of Clinical Oncology (ASCO) [Apri]
Neoplasie della mammella, Linee Guida AIOM, 2018 [Apri]
ESMO Clinical Practice Guidelines: Breast Cancer [Apri] A service of the U.S. National Institutes of Health [Apri]
Referenze bibliografiche specifiche
Mackey J, et al. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. Annals Oncol 2016;27:1041-1047 [Apri]
Gianni L, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 2014;15:640-647 [Apri]
Von Minckwitz G, et al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).Ann Oncol 2013;25:81-89 [Apri]
Musolino A, et al. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer 2011;117:1837-1846 [Apri]
Slamon D, et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. N Engl J Med 2011;365:1273-1283 [Apri]